Pharmaceutical Product Development 8-K 2010
Documents found in this filing:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 1)
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 26, 2010
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
Registrants telephone number, including area code (910) 251-0081
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
This Form 8-K/A is being filed to amend Exhibit 99.3 contained in the original Form 8-K filed on October 26, 2010 to provide additional information included in the GAAP/non-GAAP reconciliation presentation posted on the website of Pharmaceutical Product Development, Inc. Except as otherwise noted, no other changes have been made to the original Form 8-K, and this Form 8-K/A does not modify or update any other information in the original Form 8-K.
On October 26, 2010, Pharmaceutical Product Development, Inc., or PPD, issued a press release announcing its financial and operating results for the three months and nine months ended September 30, 2010. A copy of the press release is attached hereto as Exhibit 99.1. In addition, PPD posted on its website a business segment presentation and a GAAP/non-GAAP reconciliation presentation. Copies of these presentations are attached hereto as Exhibits 99.2 and 99.3.
The information in this Form 8-K (including Exhibits 99.1, 99.2 and 99.3) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.